These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25338958)

  • 21. [Correlation of HBV genotypes to the therapeutic effect of PEG-interferon and the pathological changes of the liver of chronic hepatitis B patients].
    Shen JK; Hou JL; Pang XN; Yang H; Xu ZJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1217-8. PubMed ID: 18676267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study on the correlation of the effect of entecavir on Th1/Th2 cytokines level in the treatment of chronic hepatitis].
    Li L; Jing YB; Liu J; Wang CL; Liu B
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):606-611. PubMed ID: 29056011
    [No Abstract]   [Full Text] [Related]  

  • 23. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection.
    Peng G; Li S; Wu W; Sun Z; Chen Y; Chen Z
    Immunology; 2008 Jan; 123(1):57-65. PubMed ID: 17764450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon.
    Boglione L; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    J Viral Hepat; 2015 Mar; 22(3):318-27. PubMed ID: 25060765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of T regulatory cells with natural course and response to treatment with interferon-α in patients with chronic hepatitis B infection.
    Xu HT; Xing TJ; Li H; Ye J
    Chin Med J (Engl); 2012 Apr; 125(8):1465-8. PubMed ID: 22613654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon therapy of chronic hepatitis B.
    Brunetto MR; Bonino F
    Intervirology; 2014; 57(3-4):163-70. PubMed ID: 25034484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissection of a circulating and intrahepatic CD4(+)Foxp3(+) T-cell subpopulation in chronic hepatitis B virus (HBV) infection: a highly informative strategy for distinguishing chronic HBV infection states.
    Zhang M; Zhou J; Zhao T; Huang G; Tan Y; Tan S; Fu X; Niu W; Meng G; Chen X; Shang X; Liu D; Ni B; Wang L; Wu Y
    J Infect Dis; 2012 Apr; 205(7):1111-20. PubMed ID: 22357657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation.
    Koay LB; Feng IC; Sheu MJ; Kuo HT; Lin CY; Chen JJ; Wang SL; Tang LY; Tsai SL
    Hum Immunol; 2011 Sep; 72(9):687-98. PubMed ID: 21215784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Lower PBMC Estrogen Receptor α Gene Expression in Chronic Hepatitis B Is Associated with a Sustained Virological Response to Pegylated Interferon.
    Zhang T; Zhang Z; Zhang Y; Ye J; Li X
    J Interferon Cytokine Res; 2016 Feb; 36(2):120-8. PubMed ID: 26485345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection.
    Fan R; Lan Y; Chen J; Huang Y; Yan Q; Jiang L; Song S; Li Y
    Virol J; 2016 Jan; 13():14. PubMed ID: 26809262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Peng CY; Lai HC; Li YF; Su WP; Chuang PH; Kao JT
    Aliment Pharmacol Ther; 2012 Feb; 35(4):458-68. PubMed ID: 22225574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy.
    Huang YW; Lin SC; Wei SC; Hu JT; Chang HY; Huang SH; Chen DS; Chen PJ; Hsu PN; Yang SS; Kao JH
    Antivir Ther; 2013; 18(7):877-84. PubMed ID: 23744559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer.
    Trehanpati N; Vyas AK
    Scand J Immunol; 2017 Mar; 85(3):175-181. PubMed ID: 28109025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB; Golge N; Akin MS
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
    Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.